The Announcement
ZS, a global professional services and technology company serving the life sciences industry, today announced the acquisition of Trials.ai, an AI-powered clinical study design platform headquartered in San Diego, California. The acquisition brings together ZS's four decades of life sciences expertise and its global network of pharmaceutical and biotech partners with Trials.ai's purpose-built AI and data platform for clinical trial design.
Trials.ai will continue to operate as Trials.ai by ZS, maintaining its product identity, leadership team, and technology roadmap - now accelerated with the resources, partnerships, and reach of ZS's global organization.
About Trials.ai
Founded in San Diego with a mission rooted in personal loss and professional urgency, Trials.ai set out to dismantle the archaic, document-driven processes that slow clinical trial design. The company's platform was built on four foundational elements:
- The Clinical Studies Ontology: a 500K+ class knowledge framework connecting clinical study concepts across standards and terminologies
- The Banzai data ingestion pipeline: NLP and LLM-powered document digitization and structuring
- A dynamic data graph: a linked graph of study data nodes enabling contextually relevant AI recommendations
- A suite of APIs and MCPs connecting to upstream and downstream clinical systems
Trials.ai's flagship application, Smart Designer, enables clinical scientists to build optimized study designs with AI-powered recommendations, real-time patient burden scoring, benchmark comparisons, and automated downstream document and system connection - saving weeks from the study design process.
"Together, we're accelerating the path from study concept to patient impact. Because patients don't have time to wait."
The Strategic Rationale
For ZS, the acquisition addresses a critical gap in the clinical development toolset. Clinical study design - the upstream process that defines everything downstream - has remained largely untouched by digital transformation. Protocols are still authored in Word, schedules built in spreadsheets, and downstream documents written by hand.
Trials.ai's platform directly addresses this gap with a purpose-built, AI-native approach. Combined with ZS's existing clinical development capabilities - spanning regulatory strategy, clinical operations consulting, data science, and a global life sciences client network - the acquisition creates an integrated offering covering the full clinical development lifecycle, from study concept to regulatory submission.
For Trials.ai, the acquisition provides access to ZS's global network of top-20 pharmaceutical clients, its deep clinical development domain expertise, and the organizational resources to accelerate product development and scale customer success. Most importantly, it provides the platform to pursue the company's mission at the scale the problem demands.
"What Trials.ai has built is exactly what the clinical development industry needs - a purpose-built, AI-native platform that treats the protocol as data, not a document. This acquisition accelerates our mission to transform clinical development and ultimately get better therapies to patients faster."
ZS LeadershipWhat It Means for Customers
For existing Trials.ai customers, the acquisition means continuity of the platform they rely on - with accelerated development velocity and the expanded capabilities that come from ZS's resources. The Trials.ai product roadmap continues and accelerates, with additional investment in the platform's AI capabilities, data assets, and ecosystem integrations.
Customers also gain access to ZS's broader clinical development expertise, including regulatory strategy, clinical operations consulting, and data science capabilities that can complement the Trials.ai platform. The combination creates a uniquely integrated offering: a technology platform backed by deep domain expertise.
For ZS clients who have not yet engaged with Trials.ai, the acquisition adds a purpose-built clinical study design platform to ZS's technology portfolio - natively aligned with emerging standards like USDM and built for the AI era of clinical development.
Looking Forward
The combination of Trials.ai's platform and ZS's life sciences expertise creates a distinctive position in the market: a technology company with the domain depth of a consulting firm, and a consulting firm with a world-class technology platform at its core. This combination is increasingly rare - and increasingly valuable - as the life sciences industry navigates the transition from document-driven to data-driven clinical development.
Trials.ai by ZS will continue to invest in the platform's foundational capabilities - the Clinical Studies Ontology, the Banzai Pipeline, Franklin Connected Intelligence, and Smart Designer - while expanding the ecosystem of downstream connections, standards alignments, and data assets that make the platform more valuable with every study designed.
The mission remains unchanged. Because patients don't have time to wait.